Abnormal Circulating Collagen Degradation Product Concentration C5539552
Elevated collagen degradation products are markers of increased connective tissue breakdown. They may indicate bone disorders, liver disease, or other conditions affecting collagen metabolism. Treatment focuses on identifying and managing the underlying cause.
Key facts at a glance
- ICD-10
- M79.9
- ICD-11
- FA00.0
- Body system
- musculoskeletal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Bone pain
Deep, aching pain in bones that may be worse at night or with weight-bearing.
Seek immediate care if bone pain is severe, persistent, or accompanied by fever, weight loss, or night sweats.
Aortic aneurysm risk
Weakening of the aortic wall that may lead to abnormal ballooning or rupture of the major blood vessel.
Seek immediate emergency care for sudden, severe chest or back pain, dizziness, or signs of shock.
Joint pain
(musculoskeletal)Persistent pain in one or more joints, often worse with movement or weight-bearing activities.
Frequency: 70-80% of patients
Fatigue
(constitutional)Persistent tiredness and lack of energy that does not improve with rest.
Frequency: 65-75% of patients
Easy bruising
(dermatologic)Bruises appearing frequently or with minimal trauma due to weakened connective tissue and blood vessels.
Frequency: 40-50% of patients
Joint stiffness
(musculoskeletal)Reduced range of motion in joints, particularly noticeable in the morning or after periods of inactivity.
Frequency: 35-45% of patients
Skin fragility
(dermatologic)Thin, delicate skin that tears or bruises easily with minimal friction or trauma.
Frequency: 15-20% of patients
Muscle weakness
(musculoskeletal)Reduced muscle strength making it difficult to perform usual physical activities.
Frequency: 10-20% of patients
Delayed wound healing
(dermatologic)Cuts, wounds, or surgical incisions taking longer than normal to heal.
Frequency: 10-15% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Collagen synthesis support
Pharmacological agents that support connective tissue formation may help normalize elevated collagen degradation products. Treatment targets the underlying cause of increased turnover.
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Collagen-supportive nutrition
Adequate protein intake with emphasis on amino acids proline and glycine supports connective tissue synthesis. Include bone broth, lean meats, fish, eggs, and vitamin C-rich foods to support collagen production.
Additional treatment options
Joint protection strategies
Physical therapy focusing on joint mechanics, proper movement patterns, and muscle strengthening reduces abnormal stress on connective tissues. Customized exercise programs address specific affected areas.
physical_therapyCollagen peptide supplementation
Hydrolyzed collagen supplements may reduce markers of connective tissue breakdown and support tissue repair. Evidence supports benefits for joint and skin connective tissue health.
complementaryBone and connective tissue markers
Tracking collagen degradation and formation markers over time helps assess treatment effectiveness. Serial measurements guide ongoing management decisions.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Circulating Collagen Degradation Product Concentration C5539552?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020;105(3):dgaa048.
Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22(2):391-420.
Johansson H, Oden A, Kanis JA, McCloskey EV, Morris HA, Drake C, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture. Osteoporos Int. 2014;25(8):2187-2198.
Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393(10169):364-376.
Garnero P. The utility of biomarkers in osteoporosis management. Mol Diagn Ther. 2017;21(4):401-418.
Bauer DC, Black DM, Bouxsein ML, Lui LY, de Papp AE, Grauer A, et al. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with teriparatide or alendronate. J Bone Miner Res. 2012;27(8):1627-1634.
National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014;25(10):2359-2381.
Kanis JA, Johnell O, Oden A, De Laet C, Delmas P, Eisman JA, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000;11(8):669-674.
Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. Osteoporos Int. 2009;20(6):843-851.
World Health Organization. Prevention and management of osteoporosis: report of a WHO scientific group. WHO Technical Report Series No. 921. Geneva: WHO; 2003.
Medication Comparisons
Compare medications used to treat Abnormal Circulating Collagen Degradation Product Concentration C5539552. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy